In this review:
We have entered an age of oncology where we can now use molecular information from patients and their tumours to match treatments in ways that would have been unthinkable only a decade ago. It is a world in which almost every tumour has the potential to have a molecularly matched drug – if the testing and appropriate drug are accessible.
The studies summarised in this issue provide a brief snapshot of the many ways in which appropriate genomic testing, at the right time for patients, can impact on their existing management and provide information for family members. In forthcoming issues, we will explore in more detail the potential gains we can make for patients through molecular testing and precision medicine.
Download PDF